Balloon-assisted thrombectomy showed high recanalization rates in 45 stroke patients undergoing endovascular therapy.
This retrospective cohort study assessed the short-term efficacy and safety of balloon-assisted thrombectomy (BAT) in a population of 45 stroke patients who underwent endovascular therapy. The study was conducted at the Department of Neurology, Dongguan Hospital of Traditional Chinese Medicine, with a follow-up period of 90 days. No comparator group was reported, and the study phase and publication type were not reported.
Regarding primary recanalization, first-pass mTICI ≥2b was achieved in 75.56% of cases, while final mTICI 2b-3 was achieved in 100% of cases. The puncture-to-recanalization time was 35 min, with a 95% CI of 23.50–51.00. At 90 days, 73.33% of patients were independent (mRS 0–2), and 42.22% achieved an optimal EQ-5D-5L health state. All-cause mortality at 90 days was 2.22%.
Safety data were not reported, including specific adverse events, serious adverse events, discontinuations, or tolerability. A longer puncture-to-reperfusion time was identified as an independent predictor of favorable 90-day clinical outcome (mRS ≤2), with an OR of 0.878 (95% CI: 0.793–0.973). No p-value was reported for this association.
Limitations include the small sample size, lack of a control group, and absence of reported adverse events. As an observational study, these results cannot confirm causality or generalizability. Clinicians should interpret these findings as preliminary evidence of BAT performance in this specific setting.
View Original Abstract ↓
Intravenous tenecteplase improves functional outcomes but increases hemorrhage risk in non-large vessel occlusion acute ischemic stroke.
Tenecteplase improves stroke recovery but increases bleeding risk in late treatment window
Related in Neurology
From Other Specialties
